A Study to Evaluate ALN-6222 in Participants With Obesity
Recruiting
Phase 1
Interventional Study
Obesity
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 88 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria -
* Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2
* Has a hemoglobin A1c \<6.5%
Exclusion Criteria -
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN)
* Has known human immunodeficiency …
Contacts